Funding sources: The study was supported by Ariosa Diagnostics, Inc.
Clinical experience of noninvasive prenatal testing with cell-free DNA for fetal trisomies 21, 18, and 13, in a general screening population
Article first published online: 15 MAR 2013
© 2013 John Wiley & Sons, Ltd.
Special Issue: Noninvasive Prenatal Testing Using Maternal Plasma DNA: Part I
Volume 33, Issue 6, pages 580–583, June 2013
How to Cite
Fairbrother, G., Johnson, S., Musci, T. J. and Song, K. (2013), Clinical experience of noninvasive prenatal testing with cell-free DNA for fetal trisomies 21, 18, and 13, in a general screening population. Prenat. Diagn., 33: 580–583. doi: 10.1002/pd.4092
Conflicts of interest: TM and KS are paid employees of Ariosa Diagnostics, Inc.
- Issue published online: 17 MAY 2013
- Article first published online: 15 MAR 2013
Evaluate noninvasive prenatal testing (NIPT) with cell-free DNA as a screening method for trisomies 21, 18, and 13 in an obstetrical clinical practice setting.
Observational study of pregnant women who underwent prenatal screening for fetal trisomy from 30 July 2012 to 1 December 2012. NIPT was offered to all patients in addition to first trimester combined screening (FTS).
The cohort included 289 women with mean age of 32.3 years (range: 17.8–42.0) who underwent testing at 13.0 gestational age weeks (range: 10.1–20.7). NIPT results were provided for 98.6% of patients at a mean reporting time of 9.3 calendar days. With NIPT, all patients had a risk less than 1:10 000 for trisomy 21, 18, or 13. With FTS, 4.5% of patients had screening results indicating an increased risk for trisomy 21. One patient who had an elevated trisomy 21 risk with FTS elected to have an amniocentesis, which revealed a euploid fetus.
NIPT has the potential to be a highly effective screening method as a standard test for risk assessment of fetal trisomies 21, 18, and 13 in general pregnant populations. © 2013 John Wiley & Sons, Ltd.